FDA Approves BridgeBio's Attruby for Heart Disease

BridgeBio Pharma Inc. has received U.S. FDA approval for Attruby, an oral medication designed to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a severe heart condition. This new drug is positioned to compete directly with Pfizer's established treatment, Vyndaqel, in a rapidly growing market. Attruby is notable for being the first drug with a label indicating near-complete stabilization of transthyretin proteins, significantly reducing mortality and related hospitalizations in clinical trials. Priced at $18,759 for a 28-day supply, BridgeBio will also provide the drug free for life to U.S. clinical trial participants. The approval follows promising results from the ATTRibute-CM Phase 3 study, which showed substantial benefits for patients. BridgeBio anticipates strong competition ahead as it enters a market previously dominated by Pfizer.